Version history

{
  "session_id": "sess_ext_h-2600483e_20260428_051452",
  "round_number": 6,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "llm",
  "action": "synthesize",
  "content": "\n\n# Scientific Synthesis: CYP46A1 Overexpression Gene Therapy for Neurodegeneration\n\n## Dimension Scores\n\n| Dimension | Score | Rationale |\n|-----------|-------|-----------|\n| **Mechanistic Plausibility** | 0.78 | Solid biological foundation (CYP46A1 is the rate-limiting enzyme for brain cholesterol elimination), multiple interconnected pathways (lipid raft remodeling, LXR activation, SREBP signaling), but relies on unproven assumption that modest cholesterol reductions will meaningfully shift amyloid pathology |\n| **Evidence Strength** | 0.70 | Promising mouse model data (APP/PS1 and 3xTg-AD showing 40-50% Aβ reduction, memory restoration), but no human clinical data, therapeutic window for 24-OHC incompletely defined, and linear cholesterol-to-Aβ relationship inadequately validated |\n| **Novelty** | 0.58 | CYP46A1 biology is well-established; gene therapy approach adds delivery innovation but the core target mechanism has been studied for decades |\n| **Feasibility** | 0.65 | AAV-mediated delivery is technically feasible but requires BBB-penetrating strategies, neuronal tropism optimization, and raises long-term safety concerns; no selective small-molecule activators identified |\n| **Therapeutic Potential** | 0.78 | Addresses major unmet need (AD affects ~50 million globally), disease-modifying potential, multi-target mechanism offers possible synergy with existing approaches, but narrow therapeutic window and off-target effects remain concerns |\n\n---\n\n## Top 3 Cited Papers\n\n| Paper | Citation | Relevance |\n|-------|----------|-----------|\n| Astrocyte-neuron combined targeting for CYP46A1 gene therapy in Huntington's disease | DOI:10.1186/s40478-025-02054-4 | Direct gene therapy proof-of-concept; demonstrates therapeutic window achievability |\n| Cholesterol: Its",
  "evidence_cited": "[\"PMID:20457766\", \"PMID:23974665\", \"PMID:25269924\", \"PMID:29885487\", \"DOI:10.1186/s40478-025-02054-4**\", \"PMID:20876131\", \"PMID:15755746\", \"DOI:10.1089/hum.2016.087\", \"DOI:10.1186/s40478-025-02054-4)\", \"DOI:10.1016/j.redox.2017.10.014)\", \"DOI:10.1089/hum.2016.087)\", \"DOI:10.1186/s40478-025-02054-4\"]",
  "tokens_used": "448",
  "persona_id": "persona-synthesizer"
}